TORONTO, June 6 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a developer of medical imaging systems for the operating room, announced today that Dr. Arun Menawat, President & Chief Executive Officer, will present the corporate story, technology and highlights at the Pacific Growth Equities Life Sciences Growth Conference. The conference runs from Monday, June 12 through Wednesday, June 14 at the InterContinental Mark Hopkins Hotel in San Francisco. Dr. Menawat presents at 10:30 am on Tuesday, June 13 in the California Room. About Novadaq Technologies Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular, ophthalmic, and neurologic diseases and conditions. Novadaq's SPY(R) Intra-operative Imaging System, commercially available worldwide, enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during the course of open- heart bypass surgery. Novadaq's ophthalmic product, the OPTTX(R) System, is aimed at the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY System. The OPTTX System is currently being evaluated in clinical trials. Novadaq's product for nerve visualization in prostate surgery, LUNATM is being developed to enable surgeons to visualize nerve bundles during the course of radical prostatectomy in order to reduce negative outcomes including impotency. For more information, please visit the company's website at www.novadaq.com. Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings; actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. %SEDAR: 00022069E
Novadaq to present at Pacific Growth Equities Life Sciences Growth Conference
Novadaq Technologies Inc. on 6ix
Earlier from Novadaq Technologies
- Novadaq announces LUNA highlights from AUA 2006
- Novadaq Technologies notice of annual meeting
- Novadaq Announces Study Results Presented at the American Heart Association's Quality Conference
- Novadaq receives FDA clearance for SPY labeling changes
- Novadaq reports financial results for first quarter of 2006
Later from Novadaq Technologies
- Novadaq to present at Orion Securities Annual Healthcare Conference
- Novadaq Meets Key Commercialization Milestone with 50th SPY System
- Novadaq to hold second quarter 2006 conference call and webcast
- Novadaq Reports Financial Results For Second Quarter Of 2006
- Novadaq hires Divisional Vice President of Sales, Cardiac
Follow Novadaq Technologies into a list and get an email when it puts out news.
Follow Novadaq Technologies